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1
INTRODUCTION

Cancer and the neoplastic cell

Cancer is a class of diseases characterized by the pathological generation
of abnormal cells. The cancer begins as a localized growth that may spread
throughout the body by the circulatory and lymphatic pathways. The poorly
regulated cell division is caused by damage to the DNA and to mutations in genes
that control cell division. Several mutations are required to turn a cell completely
neoplastic, meaning that the transition from a normal cell to a cancerous
(neoplastic) one can be a gradual process sometimes requiring years. Thus, each
cancer is the end result of multiple changes within a single cell lineage that have
taken place during the life of the affected cell or even within the germ line of the
host. The critical biological changes within the cell that accompany its neoplastic
transformation involve an altered response to mechanisms that control cell
growth, differentiation, and senescence. Although there are many types of cancer,
depending on the cell type of origin (connective tissue, hematopoietic tissue, or
epithelial tissue), each grows and spreads in its own way and causes its own set of
symptoms.
Cancer cells have many key behaviors that differentiate them from normal
cells. One characteristic of the neoplastic cell is a reduced dependence on signals
from other cells for its growth, survival, and division. Often, this is because they
contain mutations in components of the cell signaling pathways through which the
cells respond to such social cues. Neoplastic cells also have prolonged survival
rates and are less prone to kill themselves by apoptosis than non-cancerous cells.
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This aversion to suicide is often caused by mutations in genes that regulate the
intracellular death program. A third characteristic of neoplastic cells is their
ability to proliferate indefinitely. Most normal human somatic cells will divide
only a limited number of times in culture, after which they permanently stop
because the telomeres on the ends of the chromosomes become too short. Cancer
cells typically break through this barrier by reactivating production of the
telomerase enzyme that maintains telomere length.
In addition, neoplastic cells are often genetically unstable, because they
have a greatly increased mutation rate and often have an impaired ability to repair
damaged DNA. They can become invasive by changes in cell-adhesion
molecules that hold normal cells in their proper place, by generating enzymes that
allow them to invade through tissues, and by acquiring the ability to move.
Lastly, cancer cells can often survive and proliferate in secondary tissues to form
metastases, whereas most normal cells do not migrate from their original position
to other sites in the organism.
Once cells have converted into the neoplastic phenotype, they can become
invasive and often even metastatic. This invasive property allows them to
penetrate their surrounding normal tissue barriers and move to a new location
within the body, producing secondary tumors. This establishment of secondary
tumors in the body is known as metastasis and proceeds through a clearly defined
cascade of events. The first step of the cascade is the enzymatic digestion of the
basement membrane, which allows the cell access to connective tissue and an
avenue to detach from the primary tumor (McKinnell et al., 1998). The ability of
a cell to detach and move is a fundamental property that malignant cancer cells
exhibit. After the cells detach from the primary tumor, they have the ability to
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move and invade a secondary location. The invasion of the cell into an adjacent
tissue depends on the motility of the cell. Cancer cells can disseminate via
capillary and lymphatic vessels (McKinnell et al., 1998). Once inside the
capillaries, the cancer cells have the ability to adhere to one another, as well as to
lymphocytes and platelets, forming emboli that can be stabilized by fibrin clotting
(McKinnell et al., 1998). The circulating cancer cells can arrest at a secondary
location and grow at that site completing the dissemination of malignant cells.
Metastasis of cancer accounts for much of its lethality. Interruption of any of the
steps of the cascade has the potential to disrupt the malignant spread and limit the
malignant pathology. In cancer, because cell production is not balanced with cell
loss, the cell population increases in number. Genetic instability leads to the
generation of diverse cell variants, some of which may be able to metastasize to
new locations. The lungs and the liver are the two most common sites for
metastasis in the human body. Once in a new site, a cell must again penetrate the
basement membrane of the blood vessel and establish itself in the new tissue, for
its own growth and survival.

The Cell Cycle and its Regulation

The cell cycle is a sequence of duplication and division of the cell. The
function of the cycle is to duplicate DNA in the chromosomes and then precisely
distribute the copies into genetically identical daughter cells. The cell cycle
includes the manufacturing of DNA synthesis enzymes, the doubling of DNA, the
synthesis of mitosis proteins, and then mitosis--the cell division. The period
between one M phase (mitosis and cytokinesis) and the next M phase is called
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interphase. Interphase is divided into the remaining three phases of the cell cycle.
The cycle begins with G1 and ends each round with a doubling of the cell. The G1
phase is the first of the four stages of the cell cycle in which new organelles are
synthesized and DNA synthesis enzymes are manufactured. This phase is
remarkably longer than other phases because the daughter cells remain in G1 until
they receive a stimulus to enter the S phase (Alberts et al., 2004). The S phase is
the synthesis stage in which nuclear DNA is replicated. At the end of this stage,
the cell contains two complete sets of DNA. The G2 phase follows the S phase
and is a relatively short, pre-mitotic phase. Through internal biochemical
changes, RNA and other specialized proteins are produced that will aid in the
process of mitosis. The M phase is the final stage of the cell cycle and is a
continuous process of cell division. However, it can be divided into four subphases that are marked by unique events.
The first event of mitosis occurs in prophase, in which the chromatin is
transformed into chromosomes, with each chromosome composed of a pair of
filaments called chromatids (Alberts et al., 2004). Also during prophase, the
nuclear membrane disappears. During metaphase, the second phase of mitosis,
the chromosomes align between the centrioles at the equatorial plate. They are
positioned in such a way that when the chromatids separate, each daughter cell
will have a complete set of chromosomes. Anaphase, the third phase, is marked
by the separation of the sister chromatids and the formation of two daughter
chromosomes, in which each chromosome is pulled toward the pole that it faces.
The contractile ring also assembles during anaphase. During the final stage of
mitosis, telophase, the two sets of daughter chromosomes arrive at the poles of the
spindle, the nuclear membrane reforms, the chromatin expands, and the cytoplasm
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divides. It is this stage in the process, when the cytoplasm divides, that is the
focus of my research. This step, called cytokinesis, includes the furrowing of the
cell, in which the contractile ring pinches off to place one nucleus in each cell.
With the accomplishment of this step, two new daughter cells identical to the
parent cell have been formed.
Progress through the cell cycle is achieved by two different cell cycle
control mechanisms. These two mechanisms ensure correct advancement through
the cell cycle by regulating the cell cycle machinery. The first type of control
involves a series of phosphorylations by kinase enzymes and dephosphorylations
by phosphatases that activate or inactivate proteins and complexes that initiate
and regulate phases of the cell cycle. These kinases that participate in
phosphorylation combine with cyclins to become enzymatically active. The
activation/de-activation of these cyclin-kinase complexes trigger and help time
various cell cycle events (Alberts et al., 2004).
A second type of cell cycle regulation is checkpoint control. It is not an
essential part of the cell cycle, but is more supervisory. Specific checkpoints
throughout the cycle sense flaws in critical events of the cycle. If one of the steps
is delayed, or a flaw is detected, such as abnormal size, the control system will
delay the activation of the next steps until the intracellular and extracellular
conditions are favorable (Collins et al., 1997). There are two such checkpoints in
the cell cycle that serve as molecular brakes. The first checkpoint lies in the G1
phase and detects damage of the DNA. If the cell arrests in this phase, the cell
has time to repair the damaged DNA before replicating it in the S phase. Another
important cell-cycle checkpoint occurs in mitosis to ensure that all of the
chromosomes are appropriately attached to the mitotic spindle. If not all of the
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chromosomes are attached to the spindle, the cell could proceed through mitosis
with the chromosomes unevenly segregating to the poles of the cell. With both of
these checkpoints in the cell cycle, mutations and potential damage can be
averted. Thus, the cell cycle’s control system regulates and monitors the
completion of critical events and can delay the progression, if necessary.
There are also additional checkpoints within the cell cycle, independent of
the regulation of cell cycle machinery, which control such things as the actin
cytoskeleton. According to Nakaseko and Yanagida (2001), cells have the ability
to keep track of their actin cytoskeleton; if it is defective, the mitotic spindle
during mitosis will become incorrectly oriented and the cell will suppress
subsequent phases of cell division. The mitotic spindle, which serves to move the
duplicated chromosomes apart during mitosis (Alberts et al., 2004), has its own
separate checkpoint, which has been previously mentioned. Though defects in the
mitotic spindle are associated with a checkpoint of the actin cytoskeleton, the two
checkpoints are independent. What and how the actin cytoskeleton checkpoint
monitors has not been completely determined. It is known that this checkpoint
has the ability to block normal separation of sister chromatids, which can halt
progression in the cell cycle, until the organization is correct. However, not much
is known about the exact mechanism by which actin affects the spindle
orientation. It has been proposed that when the actin-based cytoskeleton
becomes damaged or disorganized, this somehow results in the spindle becoming
misoriented, which in turn activates the Sty1/Spc1 protein (Nakaseko and
Yanagida, 2001). The Sty1/Spc1 protein is a mitogen-activated protein kinase
that phosphorylates another protein called Atf1, which is involved in a stressactivated protein kinase pathway. While the exact mechanism for this is not
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known, it is clear that this stress-activated pathway is a key component of the
actin-dependent mitotic checkpoint. The ultimate result of this pathway is a
failure to segregate the duplicate chromosomes, which like any other checkpoint,
delays cell division until the organization becomes corrected.
Cell volume is additionally regulated and controlled by specific pathways
and points in the cell cycle. In eukaryotic cells, growth is regulated by
extracellular growth factors in both gap phases, G1 and G2, of the cell cycle.
While there is no definite cell-size checkpoint, there is a system that regulates and
maintains cell size that is related to the process of S phase initiation (Cooper,
2004). It has been proposed that mammalian cells initiate S phase and DNA
replication at some relatively constant cell size (initiation mass), coupled with
relatively invariant S and G2 phase times and variant interdivision times. Thus,
the cell cycle age at initiation of S phase will occur earlier and earlier within the
cell cycle as the growth rate of a cell increases (or as the interdivision time
decreases), because the cell has quickly reached the proposed initiation mass.
Because of this, faster growing cells will have a relatively short G1 phase and
become larger than average cells, making the faster growing cells divide sooner
because they reach the initiation mass earlier. In addition, smaller than average
cells will delay initiation until the initiation mass is achieved. A cell that initiates
S phase earlier in the cell cycle will have more time to increase its total mass prior
to division, and conversely, smaller cells will delay initiation of S phase to allow
for mass increase before the actual cell division. According to Cooper, this
finding suggests that normal cells must operate some sort of checkpoint in order
to maintain a constant average cell size; the checkpoint ensures that a cell does
not continue to grow after a certain size, until after division. While this cell-size
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checkpoint operates to prevent cells from getting progressively bigger and bigger,
there is presumably another checkpoint that prevents division from occurring
before the cells have reached an adequate size, in order to prevent them getting
progressively smaller.

Cytochalasin B

Cytochalasin B is an alkaloid metabolite of the mold Helminthosporium
dematiodeum produced by mold to kill off bacteria. It is known to inhibit a wide
variety of cellular movements including cytokinesis, cell locomotion, cytoplasmic
streaming, blood clot retraction, and movements associated with developmental
processes (Lin et al., 1973). Brown and Spudich (1981) reported that
cytochalasins inhibit the rate of actin assembly. Lin, Santi, and Spudich showed
earlier that cytochalasin B inhibits actin assembly by causing a decrease in the
intrinsic viscosity of actin, and an altering in the morphology of the actin
filaments, as shown in muscle and blood platelets (Lin et al., 1973). They also
suggested that there could be a possible cytochalasin B receptor on actin
microfilaments. Because they were able to show that there is a concentration
dependence on binding of cytochalasin B to different types of cells, they
concluded that there are at least two types of binding site for cytochalasin B, as
shown by their results using bovine platelets, HeLa cells, bovine red blood cells,
D. discoideum amoebae, and A. aereogenes cells (Lin et al., 1973). Lin, Santi,
and Spudich (1973) named these sites high and low affinity-binding sites.
Flanagan and Lin next observed that in fact, filamentous actin (F-actin), and not
globular actin, contained such high affinity cytochalasin B binding sites (Flanagan
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and Lin, 1980). This F-actin lies at the end of the filament where assembly takes
place, blocking the assembly end (Brown and Spudich, 1981). In our lab, we are
making use of these observations and the previous research done on cytochalasin
B to induce U937 leukemia cells into multinucleation. Multinucleation is the
process by which the actin microfilaments in cytokinesis are disrupted, resulting
in a cell accumulating more than one nucleus.

Manipulation of the cell cycle’s regulation: induction into multinucleation

Normal cells have key checkpoints in the cell cycle that signal the cell to
either delay progression until any abnormalities are corrected, or to continue
through the cycle with no interruption. If cytochalasin B was used on a
population of normal, non-neoplastic cells, the cells would halt at the second
checkpoint and direct the cell to stop dividing. This is due to the fact that
cytochalasin B prevents normal cells from entering the cell cycle because it
disrupts the actin microfilament cytoskeleton. The control system of the cell cycle
will delay the activation of the next steps, and the cell will stop dividing
mitotically in order to correct the shape and integrity of the actin cytoskeleton
before allowing entry back into the cell cycle (Law and Reed, 1995). In some
neoplastic cells, on the other hand, actin microfilament disruption induced by
cytochalasin B does not prevent cell cycle entry, but after completion of the cell
cycle and nuclear replication, the absence of a functional actin cytoskeleton does
prevent cytokinesis. The neoplastic cells have lost the key mechanism for
controlling entry into the cell cycle, and multinucleation will result. The
neoplastic cell will go into the cell cycle and make DNA, but will not be able to
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split into separate cells, thus creating multinucleation and enlargement of the
cells. Thus while normal cells exit the cell cycle and enter a G0 (resting) state,
neoplastic cells continue nuclear division, become extremely enlarged and heavily
multinucleated, and are also likely to contain elevated numbers of mitochondria
per enlarged cell.
We hypothesize that enlarged cells containing high levels of DNA and
high mitochondrial contents may enter apoptosis more readily when they
experience DNA or mitochondrial damage than will cells with normal amounts of
DNA and mitochondria. This could occur because the enlarged cells have more
targets per cell for damage by DNA-directed agents or by agents damaging
mitochondria. We further hypothesize that enlarged leukemia cells may be more
susceptible to physical damage than are normal-sized leukemia cells because of
the increased cytoplasmic volume retained by a plasma membrane with weakened
internal cytoskeletal support. In our research, we have found that U937 human
promyleocytic leukemia cells that have been treated with cytochalasin B become
heavily multinucleated, containing as many as eight or more nuclei depending on
the length of treatment time. U937 leukemia cells were chosen for this study for
two main reasons. The first characteristic of these cells that makes them ideal for
our experiments is the fact that they do not adhere to one another, making them
easy to count and individually to size. Also, the U937 leukemia cells have the
ability to grow in suspension, rather than attached to the plastic culture flask,
again making them easier to count and size reliably. With a high number of
nuclei in one single cell, we think that the internal cytoskeletal support might
weaken, and propose that sonication of the multinucleated cells may make them
more susceptible to apoptosis-induction.
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Ultrasound-induced cavitation

In medicine, ultrasound has been a widely used and well-established
diagnostic and therapeutic technique for many years (Liu et al., 1998).
Ultrasound is commonly used for soft tissue imaging because of its perceived
safety, noninvasiveness, and low cost (Feril Jr. and Kondo, 2004). Ultrasonicimaging, which uses high-frequency low-intensity ultrasound, is used to scan
organs and visualize their size and structure. This type of ultrasound does not
damage the skin or sonicated organs. At somewhat greater intensities, ultrasound
can be used therapeutically to heat tissues deep within the body. On the opposite
end of the frequency spectrum, low frequency and high intensity focused
ultrasound is often used in lithotripsy, a procedure used to break up kidney stones
within the body so that they can pass without the need for surgery (Liu et al.,
1998).
Medical ultrasound has many other applications, including cancer therapy,
which involves the process of acoustic cavitation (Feril Jr. and Kondo, 2004).
Acoustic cavitation is the process by which high intensity acoustic fields in
liquids lead to the creation and oscillation of cavities or gas bubbles (Liu et al.,
1998). Acoustic cavitation has been shown to increase the permeability of cell
membranes. This form of cavitation has been used to permeabilize cell
membranes, making it easier for materials to enter the cells without damaging
them (Lee et al., 2004). Others have shown that ultrasound transiently disrupts
cell membranes facilitating the loading of drugs and genes into viable cells
(Cochran and Prausnitz, 2001).
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The goal of my laboratory use of ultrasound is not for drug delivery.
Rather, it is to determine whether there is a sonic sensitivity of cells enlarged by
treatment with cytochalasin B that might be exploitable as a potential modality in
leukemia therapy. Using acoustic cavitation, we have developed procedures with
the potential to differentially target the enlarged U937 leukemia cells created by
treatment with cytochalasin B possibly increasing their sonic sensitivity in
comparison with untreated control cells. This physical treatment may be
applicable to enhancing the cytotoxic effects of microfilament agents in treatment
of leukemia in pre-clinical animal models.
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METHODS

Cytochalasin B enlargement of U937 leukemia cells
U937 leukemia, a human promyleocytic cell line, was used in this work.
Cells were seeded at 5.0 x 104 cells/ml in 20% fetal bovine serum in Iscove’s
medium supplemented with 2% of 10,000 units penicillin and 10 mg
streptomycin, 0.5% gentamicin sulfate, and 2 mM glutamine. The cells were
treated with cytochalasin B at concentrations ranging from 1.25 µM to 2.1 µM
and were allowed to proliferate and enlarge for thirty-six hours. After thirty-six
hours, the cytochalasin B-treated cells were spun down in a 50 ml centrifuge tube.
The tube consisted of 30 ml of cells placed carefully on top of 20 ml of phosphate
buffered saline medium (PBS) at 37˚C. The tube was spun for two and a half
minutes at 20 G. The size distribution and cell number of the enlarged,
multinucleated cells were determined with a hemocytometer using the trypan blue
dye exclusion test procedure and with a Model Z1 Beckman-Coulter Particle
Counter for both the supernatant and precipitate. This procedure is outlined
below. Figures 1 and 2 below show (without trypan blue) a population of control
U937 leukemia cells in a hemocytometer at 100X as well as after treatment with
cytochalasin B.
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Figure 1: A population of un-treated control U937 leukemia cells.

Figure 2: A population of cytochalasin B treated U937 leukemia cells.

Filtration and separation of cells
The precipitated enlarged CB-treated cells were then filtered through
nylon mesh sieve to separate the enlarged, multinucleated cells from the
unenlarged, mononuclear cells. A 4.5 cm filter was used fitted with 20 µ nylon
mesh for the sieve. A 12.5 ml aliquot of cell suspension was added to the sieve
and was then allowed to filter until the flow of the cell suspension through the
filter slowed to one drop a minute. The filtrate was then removed and saved in a
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25 ml tube to later determine its size distribution. The trapped cells on the sieve
were re-suspended and washed in 5 ml of warm equilibrated medium. Ten ml of
additional cell suspension was added to the sieve and was filtered as above. The
trapped washed cells were re-suspended once again after the second 10 ml was
filtered. The filtrate and trapped cells were counted and sized using the
hemocytometer and Coulter Counter. Both of these procedures are outlined
below.
Results from this separation procedure (see Results) provided experience
with ways to improve the separation of the enlarged cells from normal sized cells.
The filtration procedure was improved based on my results with the 20 µ nylon
mesh separation. Dr. Thomas Fondy designed a cell separation procedure to
better separate the enlarged, multinucleated cells from the mononucleated cells
for use in the sonication experiment below. For this separation procedure, U937
leukemia cells were seeded at 3.4 x 104 cells/ml in 20% fetal bovine serum in
Iscove’s medium and were treated with cytochalasin B at a concentration of 1.25
µM and allowed to proliferate and enlarge for thirty-six hours. Twenty-four ml of
the cells were centrifuged on top of 30 ml of warm PBS in a 50 ml centrifuge tube
at 20 G for 3 minutes. The upper 40 ml were removed and saved and the bottom
10 ml fraction was saved as the 20G precipitate.
A 19 µ nickel porated sieve was placed inside a crystallizing dish and cold
sterile PBS was added to 0.5 cm above the top of the sieve. The 10 ml fraction
from the 20G precipitate was added to the sieve and was allowed to settle in a
refrigerator for 30 minutes. The upper fraction from the sieve (46 ml of cells in
PBS suspension) was recovered. Ten additional ml of PBS was added to the sieve
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and the 46 ml recovered was re-sieved and allowed to settle in a refrigerator for
30 minutes. From atop the sieve, 60 ml was recovered and saved as the trapped
fraction and 42 ml was recovered from the bottom of the sieve and saved as the
filtrate. The trapped fraction was centrifuged in two 50 ml centrifuge tubes at
20 G for 3 minutes. The upper 30 ml from each tube was removed, which left
500 µl in the bottom of the two tubes. To the 500 µl, 5 ml of 20% FBS in
Iscove’s medium was added to both tubes and they were combined to give a total
of 11 ml. Ten ml was taken to form the final trapped fraction, which was diluted
with 11 ml of 20% FBS in Iscove’s medium to give 21 ml of 1.95 X 104 viable
cells/ml for use in the sonication experiment.

Ultrasonic disruption

Once the cells had been separated through use of the sieve, the cells were
then subjected to ultrasound. To create the ultrasound delivering apparatus, an
Omega pro lab timer was connected to an E/MC model 250 ultrasonic bath
cleaner with a measured mean output of 0.77 watts (see Appendix E). The
ultrasound bath was filled with 250 ml of distilled water at 37˚C. A ring stand
was also used to hold the tubes exactly at the focus point of the sonicator.
Trapped cells were suspended at 2.0 x 109 viable cells/ml in 20% FBS with
Iscove’s medium. Two ml aliquots were placed in 8 ml sterile tubes (100 mm x12
mm). The tubes were then sonicated at 0, 2, 4, 6, 8, and 10 seconds and were
done in duplicate. Un-enlarged and untreated leukemia cells at 2.0 x 104 viable
cells/ml were used as the control and were sonicated at the same lengths of time
as the CB-treated trapped fraction, as well as being done in duplicate. Each tube’s
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sample was gently re-suspended and was placed in the water so the 2 ml sample
was completely submerged. After all of the tubes had been sonicated, samples
were taken from each tube for hemocytometer counts to determine cell viability
and re-growth (see procedure below).

Determining cell viability

Determining cell viability of the U937 population was done using a trypan
blue dye exclusion test coupled with a hemocytometer. Trypan blue is one of
several stains used in this method, which is based upon the principle that viable
cells do not take up the dye whereas non-viable cells do. This occurs because
cells with an intact membrane are able to exclude the dye while cells without an
intact membrane take up the trypan blue. Therefore, all cells that exclude the dye
are scored as viable. The test was performed by mixing 50 µl of cell suspension
with an equal amount of 0.4% trypan blue stain in isotonic saline. After the stain
was added, the solution was mixed thoroughly and 12 µl of the mixture was
transferred to each of the two counting chambers of a hemocytometer.

By

means of a light microscope, the cells were recorded as either small (<20 µ) or big
(>20 µ) in size using the eyepiece reticle, and whether they were viable or not.
Using a trypan blue viability form created in Microsoft Excel and developed by
Dr. Thomas Fondy (see Appendix A), the total percent viability and cell size were
calculated for the population. Figure 3 below shows an example of a slide that
contains both enlarged, multinucleated cells and un-enlarged cells, and that have
either taken up or excluded the dye.
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Figure 3: A population of viable and non-viable cytochalasin B treated
U937 leukemia cells.

Measuring cell size

The size distribution of the cell suspension was determined using the
Coulter Counter. The Coulter Counter is an instrument designed to analyze
particle size by calculating the measurable changes in electrical resistance
produced by nonconductive particles suspended in an electrolyte. Using a small
round-bottomed cuvette, 1 ml of cell suspension was added to 14 ml of isotone for
a dilution factor of 15. A blank was also prepared with 15 ml of isotone and was
run first before the samples to ensure that the background particle count was low.
The instrument was set at a desired particle threshold to obtain the number of cells
that are equal to or bigger than the setting (for example, ≥19 µ finds the total
number of cells that are at least 19 µ.) The aperture tube was flushed between
each analysis and the sample was gently stirred with a glass rod to evenly re-
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suspend the cells, but to avoid damaging the cells or getting air bubbles. A 0.5 ml
sample was counted. The cell number per ml was determined by multiplying the
particle count by 2 and by the dilution factor. Dr. Thomas Fondy developed
Coulter Count forms using Microsoft Excel (see Appendix B), which allowed us
to determine the number of cells at each increasing micron from 10 µ to 30 µ and
also calculate the percentages of cells of various diameters.

Determining nuclear content

The number of nuclei in a cell was determined by DAPI (4', 6-Diamidino2-phenylindole) staining techniques. The DAPI stain was used because it could
form fluorescent complexes with natural double-stranded DNA. The procedure
involved mixing 1 ml of cells at a density of 1x105 cells/ml with 0.5 ml of 10%
formalin solution. Formalin was used because it has the ability to kill and fix the
cells so that they would maintain their shape and structure without loss of nuclear
content. The cells were left in the formalin overnight, and the next day the
suspension was centrifuged for 90 seconds at 1,500 RPMs, or 500 G. Care was
taken not to exceed 2,100 RPM because this may damage the cellular integrity.
The cells appeared as a small pellet on the bottom of the microfuge tube. The
supernatant was removed and 5 µl of DAPI (concentration 1 µg /µl) was added to
the pellet. After being carefully mixed, 5 µl of the cells in the DAPI suspension
were added to a slide and the slide was sealed with a cover slip. Under a
fluorescent microscope, the number of nuclei in each cell was recorded. Figures 4
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and 5 show visual differences in the number of nuclei seen in both small,
mononuclear U937 cells and enlarged, multinucleated U937 cells.

Figure 4: U937 leukemia cells that have been enlarged and multinucleated by
treatment with cytochalasin B.

Figure 5: Control mononucleated U937 leukemia cells.
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RESULTS

Separation of the enlarged, multinucleated cells

The effectiveness of the separation technique using the 20 µ nylon mesh
sieve was determined by measuring the percentage of all trapped •19
19 µ cells in
comparison with the percentage of all •19
19 µ cells in the unseparated population
and in the nylon mesh filtrate. The percentages of total cells sieved that were
recovered in the trapped and filtrate fractions were determined in a recovery
analysis. The dye exclusion viability and extent of multinucleation were
determined for the trapped fraction. The cell sizing and counting were done using
a Coulter Counter and hemocytometer (see Methods). Before the cell suspension
was sieved, the proportion of cells that were •19
19 µ was 67%, as seen in Table 1
and Figure 6, and the trypan blue viability was 77%. After the filtration, the
proportion of cells •19
19 µ in the filtrate was reduced to 52%. This population was
74% of the total sieved. The trapped cells showed 44% of the cells were •20
20 µ. A
Coulter count at 19 µ was not done for the trapped cells. The trapped portion
showed 82% trypan blue viability. Of the viable cells, 93% were enlarged

(•20
20

µ). Thirteen percent of the total cells sieved were recovered in the trapped
fraction. The total recovery in the filtrate and trapped fractions was 87%. This
data can be seen in Table 1 below.
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Table 1: 20 µ Nylon Mesh Separation of CB-Treated U937 Leukemia Cells
(1.0 µM CB, 3 days, 10% FBS Medium)

Fraction

Volume
(ml)

Total
Cells/ml
(in 104
units)

Total
Cells (in
104 units)

Recovery
(%)

Trypan
Blue
Viability

Cells 15 µ to
19 µ (% of
Total)

Cells >19
µ (% of
Total)

Cells
>25 µ
(% of
Total)

Unseparated

22.5

1.8

40.5

100

77%

33

67

26

Filtrate

~30

1.0

30

74.1

-----

48

52

19

Sieve
Trapped

~13

0.4

5.2

12.8

82%

56

44

37

The trapped fraction from the sieve contained a higher percentage of the
biggest cells (>25 µ) than the filtered fraction, as seen in Table 1 and Figure 6.
Thus, the nylon mesh sieve did preferentially trap the bigger enlarged cells.

Figure 6: Percent of total cells >14 µ of the unseparated CB-treated U937
leukemia cells and the trapped and filtered fractions after sieve separation.
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Ultrasonic disruption of the U937 leukemia cells

To determine whether there was a sonic sensitivity in cells treated with
cytochalasin B, control U937 cells and CB-treated U937 cells, taken from the
>19 µ trapped fraction after separation, were exposed in duplicate to ultrasound at
a power of 0.77 watts for varying lengths of time, specifically, 0, 2, 4, 6, 8, and 10
seconds (only one tube was exposed to 10 seconds). The data for the CB-treated
cells can be seen in Appendix C. (The controls are not listed.) Data are shown
for 0, 2, 4, 6, 9, and 11 days post-sonication; however, both CB-treated tubes
sonicated at four seconds and the single CB-treated tube sonicated for ten seconds
could not be counted at 11 days due to mold growth. In addition, one tube at four
seconds and one tube at ten seconds for the controls had mold growth by day 9, so
the data used is only for one tube at day 9. The controls reached confluency by
day 6 and the CB-treated cells reached confluency by day 11, so the effect of latestage mold growth in these tubes is of minor importance.
In the regrowth counts for the CB-treated enlarged cells, by day 9, the
proportion of cells that were >19 µ were between 2% and 14%. By day 11, no
viable big cells were seen in the 0, 2, 6, and 8 second tubes, the tubes that had no
mold growth. This can be seen in Figure 7.
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Percent of Big Cells Post-Sonication
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Figure 7: Percent of Big Cells Post Sonication.

As seen in Figure 7 and Appendix C, the percent of the total enlarged, big
cells for the CB-treated tubes decreased overall as a function of the length of time
(in days) post-sonication. As the number of elapsed days after sonication
increased, the initial viable big cells either died or may have turned into small
cells due to cell division. By day 9, the average percent of trypan blue positive
(dead) enlarged cells was 58%, compared with 11% for day 2. The few viable big
cells seen on day 9 could have been mitotic cells that were dinucleated and
enlarged; normal U937 leukemia cells typically have around 3% of their cells
enlarged due to mitosis.
After the tubes were sonicated at their respective time intervals on day 0,
the initial day 0 counts were determined as the initial reference point for later
regrowth counts, and also to determine whether sonication affected cell size
distribution, especially in the enlarged CB-treated tubes. As seen in Figure 8,
there was a fairly consistent effect on the number of big viable cells per milliliter
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immediately after sonication. While the number of big cells per milliliter did
decrease from 0 seconds of sonication (i.e. no sonication) to 6 seconds and they
increased again from 6 to 10 seconds of sonication, showing no clear trend.
However, combining all nine sonicated tubes versus the non-sonicated, 0 second
tubes shows an average of a 71% decrease of big viable cells per milliliter as a
result of sonication, suggesting that there was an effect.
Extent of Sonication on Viable Big Cells at 0 Days

Big viable cells/ml in 10^4 units

2.5
n=1

2

1.5
Average of all
sonicated tubes= 0.58,
standard error= 0.31

1

0.5
n=2 for all time amounts except for
10 secs, where n=1

0
0

2

4

6

8

10

Amount of Sonication (secs)

Figure 8: Viable Big Cells Immediately After Bath Sonication.

In addition to decreasing the proportion of big viable cells, sonication also
affected the subsequent growth rate of the CB-treated cells. The cell counts at
day 2, most notably, seem to show that the growth of the viable cells was
progressively inhibited by increasing the time of sonication. This can be seen
more clearly in Table 2, which tabulates the number of cells per milliliter on day
two as a function of the amount of sonication. The growth rate of the cells does
decrease as the amount of sonication is progressively increased, reaching a
maximum 76% retardation of growth at six seconds.
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Table 2: Day 2 Regrowth Counts showing the retardation in the growth rate

Amount of Sonication
(secs)

Viable cells/ml
in 10^4 units

% of 0 secs growth rate

0

6.56

-------

2

6

91

4

4.78

73

6

1.56

24

8

2

30

10

3.56

54

Amount of growth rate
retardation (%)
-------9
27
76
70
46

Figures 9 and 10 show logarithmic plots of the concentration of viable
cells from the CB-treated tubes and for the control cells for different amounts of
sonication. Comparing the two figures, there seems to be a retardation in growth
rate for the CB-treated tubes that persisted throughout the period of observation.
Both the non-sonicated CB-treated cells and the non-sonicated control cells grew
to confluency, but the control cells reached this point roughly four days earlier
(day 6) than the CB-treated cells (~day 11). This delay in reaching confluency
shows that enlarged purified CB-treated cells retain viability, but have a lower
growth fraction and/or a longer cycling time than control U937 cells exhibit. This
is consistent with cloning efficiency determinations by Dr. Thomas Fondy where
the control U937 cells show 50% cloning efficiency, while the trapped cells show
a cloning efficiency of 5% to 8%.
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Figure 9: Regrowth of the U937 CB-Treated Small Cells after Bath
Sonication.

Figure 10: Regrowth of the U937 Leukemia Control Cells after Bath
Sonication.
The most clear cut evidence of a retardation in growth rate related to the
amount of sonication can be seen by averaging together the means for 0 and 2
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seconds and comparing these results to the comparable average means for 6 and 8
seconds. (Performing these averages improves the statistical significance of the
result.) In Figure 11 which plots the growth after sonication of the control
leukemia cells, there is no statistically significant difference between the average
of the means of the number of viable cells per milliliter of the 0 and 2 second
tubes versus the average of the means of the 6 and 8 second tubes.

Figure 11: Regrowth after Sonication of Control U937 Leukemia Cells,
0 & 2 secs vs 6 & 8 secs Tubes.

However, when the same comparison is made with the CB-treated
leukemia cells in Figure 12, a statistically significant difference can be seen
between the means of the 0 and 2 second data versus the means of the 6 and 8
second data, based on t-tests that were performed on the data for each observation
time. The differences on days 2 and 6 are statistically significant at p-value=
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0.005 and p-value= 0.02, respectively (Day 2 t-statistic=4.09, Day 6 tstatistic=3.04, df= 6). Days 4 and 9 are not statistically significant. Data at day
11 was not included due to mold growth, which lessened the sample size.

Figure 12: Regrowth after Sonication of CB-Treated U937 Leukemia Cells,
0 & 2 secs vs 6 & 8 secs Tubes.

Figure 13 plots the total number of dead control U937 leukemia cells as a
function of days post-sonication. Examining this figure, and excluding day 11,
there seems to be no effect of sonication on the control cells after day 0 since the
percent of dead cells remains approximately constant as a function of time at all
levels of sonication. (On day eleven, all the samples show an elevated count of
dead cells, perhaps because the cells had been at or near confluency for five days.)
There does, however, seem to be initial damage on the controls, evident by the
high percentages of trypan blue positive cells on day 0. Nevertheless, the highest
percentages of dead cells are in the 2, 8, and 10 second tubes, which only had 11,
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20, and 24 cells counted in the hemocytometer for 18 fields each, respectively.
(On later days, there was not a problem of a small sample size because the counts
were much larger.) Thus, sonication might have had an initial effect on the
control cells, but since the samples are so small, it is hard to tell if the effect is
real. If it is, it disappeared by day 2 once the cells began growing toward
confluency.
Percent of Control Dead Cells as a function
of time
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Figure 13: Percent of Total Dead Control U937 Leukemia Cells as a Function
of Days Post-Sonication.

The percent of CB-treated dead cells seen in Figure 14 shows a distinct
difference in the pattern of dead cells compared to the viability of sonicated
control cells. Although the CB-treated cells were initially damaged immediately
after sonication, just as the controls were, beginning at day four, the percent of
dead CB-treated cells for 8 and 10 seconds of sonication does seem to increase
and stay relatively higher than the non-sonicated CB-treated cells. Thus, there
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does seem to be a slight dose-dependent effect for the sonicated CB-treated cells
that was not seen in the sonicated control cells. This higher death rate is also
consistent with the lower growth rate of the CB-treated cells seen previously in
Figure 9.

Percent of CB-Treated Dead Cells as a
function of time
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Figure 14: Percent of Total Dead CB-Treated U937 Leukemia Cells as a
Function of Days Post-Sonication.
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DISCUSSION AND CONCLUSION

Separation of the enlarged, multinucleated cells
A great deal has been learned from our separation experiments and we
have utilized some new ideas to enhance our methods of filtration and purification
of enlarged multinucleated cells. In the separation experiment we performed
using the 20 µ nylon mesh sieve, the trapped fraction contained approximately a
52:44 ratio of small and big cells, respectively. Since >50% of the trapped
fraction was still composed of cells <19 µ, the 20 µ sieve trapped a substantial
proportion of cells smaller than 20 µ. This large percentage of small cells trapped
by the filter may have resulted because big cells blocked the filter holes so the
small cells could not flow through. We observed that the cells collected around
the edges of the mesh filter and were able to obstruct passage. Some cells larger
than 20 µ passed through the nylon mesh. Big cells that were not trapped by the
filter may have gone through the filter because of its range of hole sizes (20 ± 7 µ)
or because they were physically forced through it by net hydrodynamic flow.
Since the big cells have disrupted actin microfilaments, they are likely to be
deformable.
The separation technique was a bit more effective for cells that were
roughly • 25
25 µ since the trapped fraction contained a larger percentage of 25 µ
cells than the filtrate did, as seen in Figure 6. The filtration method was most
effective for the largest of the big cells (30 µ). Although the trapped fraction only
contained 44% enlarged and multinucleated cells, the experiment suggested
modifications to our sieving procedures that were in fact highly effective. We
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have modified many different aspects of the method in developing our improved
procedure (see Methods) to enhance and maximize the purification.
The first modification we made is probably the most important change in
regards to how the cells behave during filtration. We had previously noticed that
when the cells were added to the filter, the big cells were forced through the filter
by hydrodynamic flow. There also seemed to be many holes in the filter that were
blocked, suggesting occlusion and termination of flow. We now allow the cells to
settle through a continuous volume of phosphate buffered saline while filtrating
with no net hydrodynamic flow, rather than letting them simply drip through the
filter in a flowing medium. To do this, we use a crystallizing dish as a holder and
place the sieve within it. With a continuous liquid volume around the sieve, no
cells are forced through and have the chance to settle through the filter on their
own with no pressure involved. Before adding the cells, the sieve is submerged in
PBS until the liquid level is roughly 1 cm above the top of the sieve. Once the
cells are added and begin to settle through the medium, there is no net flow
through the filter and there is less of a chance for the big cells to be pushed
through by heavier cells above them. We did observe in the microscope that the
trapped cells bounced up and down above the sieve perforations and did not
occlude them.
Following the adaptation to the sieve apparatus, it occurred to us that the
procedure could be further improved if it were possible to partially separate the
cells before they were applied to the sieve. To do this, we began centrifuging the
cell suspension at different forces and durations to see what combination gave the
optimal separation of big and small cells in the precipitate and supernatant. After
experimenting with centrifugation of the cells, it was determined that a speed of
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200 RPM, or 20 G, was the ideal force for a period of 2 minutes. By centrifuging
the cells before they are added to the filter, we can preferentially leave the small
cells behind and concentrate the precipitate with big, multinucleated cells. Once
the concentrated cell suspension is added to the filter, it would also be easier to
see the direct effect of the sieve on the multinucleated cells if there were fewer
small cells present in the initial cell population added to the sieve.
Another modification to the filtration method we made was unit gravity
sedimentation of the cells before they are applied to the filter. The cell suspension
is first added to a syringe attached with a leur lock valve and then room
temperature PBS is added on top of the suspension to give the cells a medium to
settle in. The syringe is then inverted to allow the big cells to settle near the
plunger, and then the syringe is re-inverted so that the small cells are closest to the
leur lock valve. By doing this we can initially separate the cells inside the
syringe, thus allowing the small cells to come out first after the syringe is reinverted and followed by the bigger cells. We believe that this could help
improve the efficacy of the separation by allowing the small cells to pass through
the sieve without being occluded by big cells. This unit gravity separation using a
syringe can be used in conjunction with the centrifugation, or by itself, to
preferentially separate the cells before filtration.
Another adjustment we made to our procedure was in the filter that was
used to separate the cells. The filter originally used was a 20 µ nylon mesh sieve
followed later with a 20 µ stainless steel mesh sieve. These filters had margins of
error of about ± 7 µ. Thus, there was no guarantee that every perforated hole was
exactly 20 µ. Since many of the holes may have been bigger than expected, this
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could be the reason why some of the big cells were not trapped by the filter. After
researching sieves and materials, we found a nickel electroporated sieve that
promised to give better purification results. Because the sieve is made by an
electroporating process that forms uniform holes in a nickel plate, rather than by
weaving nylon or stainless steel mesh, it has a smaller margin of error (± 2 µ).
The sieve also has round apertures (round holes) that are not possible with woven
nylon threads or stainless steel wires. This provides uniform round perforations
rather than rectangular openings to enhance purification.
In addition, we also think that the big cells might have been pushed
through the filter because the room temperature PBS made the cells’ cytoskeleton
plastic and allowed the cells to deform without actually rupturing. To modify this
and make the cells remain rigid, we now conduct the sieve purification at 4˚C.
Lastly, we have observed that when adding cold PBS to the sterile sieve, bubbles
could collect underneath it. If this happened, many holes of the sieve were
blocked and unable to let cells flow through them, as evidenced by microscopy.
We now sterilize the sieve in distilled water to keep it wet. Before sieving the
cells, we pour off the water and add cold PBS to the sieve in the crystallizing dish
tipped to one side. This prevents any air bubbles from blocking the underside of
the sieve. With all these modifications made, our procedure has allowed us to
produce a population of CB-treated U937 leukemia cells that are 94% •19
19 µ cells.

Ultrasonic disruption of the U937 leukemia cells

In our work, we attempted to exploit the enlarged size, weakened
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cytoskeleton, and consequent increase in membrane fragility of CB-treated cells
versus control cells in producing increased sonic damage to CB-treated leukemia
cells. Previously, Dr. Thomas Fondy had found that Coulter counts showed a
shift in size distribution of the CB-treated cells to smaller cells post-sonication
(see Appendix D). In the present study, we have observed a similar effect of
sonication on cell size (Figure 7). We also found that there was a statistically
significant inhibition of growth in sonicated CB-treated cells at two and six days
post-sonication in comparison with CB-treated cells not sonicated or given two
seconds of sonication. However, further experiments would need to be completed
to determine whether the growth inhibition and shift in size distribution found in
the CB-treated cell population is reproducible and different from the effects of
sonication on the control U937 leukemia cells.
Based on t-tests that were performed to assess whether the average means
of the number of viable cells per milliliter for the combined 0 and 2 seconds data
were statistically different from the combined 6 and 8 seconds data, we can say
with 99.5% confidence that the average means of the 0 and 2 second data at day 2
for the sonicated CB-treated cells were statistically different from the average
means of the 6 and 8 second data on the same day. In addition, the difference
between the average means at day 6 was statistically significant at the 98%
confidence level. Although the difference between the two data sets on day 4 was
not statistically significant (p-value= 0.10), the data shows that there was a true
retardation effect on the growth rate of the CB-treated cells by the sonication.
Since there was no statistically significant difference seen on any day for the
control data, we can be reasonably confident that there is a difference in sonic
sensitivity of CB-treated enlarged cells in comparison with control U937
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leukemia cells.
In addition, we observed that the percent of viable big cells was reduced as
additional days passed following the sonication, compared to non-sonicated CBtreated tubes. Since the percentage of trypan blue positive big cells remained at
around 10% or higher for up to six days, it is likely that sonication killed some of
the enlarged CB-treated cells or split them into smaller cells. Viable enlarged
cells would be expected to divide in the absence of CB. This is consistent with
the reduction in cell size distribution as a function of sonication seen on day 0.
In our experiment we took data only every second day, and there was a
three-day interval after day 6. It would improve the experiment if counts were
taken at shorter intervals in order to determine when in fact, all the big viable cells
disappear for each length of time that the tubes were sonicated. With more
readings at shorter time intervals, an exact point of complete big cell
disappearance could be determined, which could make it easier to see if there
really is a clear effect that correlates with the amount of sonication. In addition,
the big cells should be observed individually by microscopic analysis to
determine the proportion that are dividing and returning to normal-sized leukemia
cells (i.e. are clonogenic) versus the proportion that have been killed by sonication
(i.e. are not clonogenic). With more refined observations of individual cells, we
could determine what is causing the big cells to be depleted in number.
The cells from the CB-treated population showed a four-day delay in
growth compared to the control cells. It appears, though, that they grew similarly
to the control cells after that, both reaching a point of confluency, although the
control cells reached that point roughly four days earlier than the CB-treated cells.
Despite the shift in growth rate, the small cells seemed to behave like the control
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cells that were never treated with CB. Whether they really do resemble control
cells in other features is not known. Since the cycle time in 20% FBS medium is
about 18 hours, a four-day difference in growth rate represents 5.3 doublings.
This indicates an 80% difference in cell viability or a slower cell cycle time for
the CB-treated enlarged, purified cells versus the control U937 leukemia cells.
Other characteristics of these CB-treated small cells would be of interest
as well. For instance, do they resist becoming enlarged when treated with a
second exposure to CB or do they represent a distinct sub-population of U937
cells with some innate feature that prevents them from enlarging and
multinucleating? Even though the leukemia cells all come from the same U937
human promyleocytic cell line, stable sub-populations could exist that respond
differently to CB. U937 leukemia forms several different types of differentiated
hematopoietic cell clones in agarose that could arise from different cell subpopulations. Further experiments into the properties of these cells need to be
performed in order to fully understand their differences.
One significant problem that was encountered in the experiment was mold
contamination in a few tubes at the late stages of regrowth. If initial mold growth
began as early as day 6 but did not become evident until day 9, the mold growth
could affect results in certain tubes showing anomalous growth. Agarose cloning,
by Dr. Thomas Fondy, of the 23 tubes showed mold growth in only two of the
tubes, and this growth appeared 15 days after seeding, demonstrating that mold
contamination on day 0 was not a problem. Contamination could have been
introduced into some regrowth tubes during the process of multiple sampling on
days 2, 4, 6, and 9. Without late stage mold contamination in some tubes, the
experiment could have been followed for additional days. However, the key
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observations had already been made by day 9, so late stage mold growth in some
tubes was apparently only of minor consequence.
One major limitation of our experiment was that we performed the
sonication with an ultrasonic bath cleaner designed to clean laboratory
instruments. In future experiments, it would be best to use a more reliable source
of ultrasound that has a power output that can be modulated and can provide
consistent levels of acoustic cavitation. We calculated the power output of the
ultrasound bath using Fourier’s law of thermal conduction based on the
temperature difference caused by the sonication and the amount of time sonicated
(see Appendix E). Using a more precise instrument with a known power output
and cavitation that can be varied would be costly, but it would make the results
more reliable and allow us to investigate sonic effects at levels less than 0.77
watts that were employed in the current experiment. This would permit a test of
longer sonication times without raising the temperature to the point where thermal
effects directly destroy the cells. If the intensity of the ultrasound could be varied
in a systematic way, it might also be possible to find the threshold intensity for
immediate disruption of the large cells.
Overall, the data demonstrate some effects that correlate directly with the
amount of sonication that was applied to the CB-treated U937 leukemia cells and
that were not displayed in the control cells. Two examples are the statistically
significant inhibited growth rate at days 2 and 6 as well as a difference in the nonsonicated versus sonicated CB-treated cells with respect to the percent of trypan
blue dead cells. One way to definitively demonstrate an effect would be to look
for a level of sonication that has a clear-cut effect on the controls and compare
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that to effects on the CB-treated cells. It is hypothesized that if a strong enough
amount of sonication is used for a long period of time, all cells would be killed.
If a differential effect of sonication on the CB-treated cells in comparison
with non CB-treated leukemia cells can be confirmed, this could potentially
introduce ultrasound as a physical modality in leukemia treatment. The sonication
could be combined with other physical and chemical modalities to potentially
enhance and increase the cytotoxic effects of microfilament agents in treatment in
pre-clinical animal models. For example, we are proposing that sonication may
have enhanced effects on enlarged CB-treated cells under hyperthermic
conditions, in hypotonic medium, or if the cells are treated with microtubuledirected agents that may render the enlarged cells even more sensitive to sonic
cavitation.
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Appendix A
Cell Viability form
Trypan Blue Cell
Counting Form
Cell Reading Date:
Conditions:

Raw

Fields Fields
Count Count
X Cells/0.1mm3 = X
TBcellx10E4/ml
Sample Being
Large
Counted
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Correct

Raw

Correct

Raw

Correct

Raw

Correct

Count/ Count/ Cells/ Count/ Count/ Cells/ Count/ Count/ Cells/ Count/ Count/ Cells/ Total

Fields

0.1

Fields

Count mm3 Count
TB-

TB-

TB-

Large Large Small

Fields

0.1

Fields

Count mm3 Count
TB-

TB-

TB+

Small Small Large

Fields

0.1

Fields

Count mm3 Count
TB+

TB+

TB+

Large Large Small

Fields

0.1

Count mm3
TB+

TB+

Raw

Total

Total

Total

%

%

Raw

Cts

Correct Cells/ Viable Viable Viable

Cts/

Add

Count/

0.1

Fields Check Fields mm3

Small Small Count

Count

Cells/

Cells

0.1

Big

mm3
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Appendix B
Coulter Count form

Coulter
Gate

Mean
Isotone
Counts

Sample
Sample
Sample Sample
Counts
Counts
Counts Mean
Reading 1 Reading 2 Reading 3 Counts

Cts Isotone

10 u
12 u
13 u
14 u
15u
16u
17 u
18 u
19 u
20 u
22 u
24 u
26 u
28 u
30 u
Sum 13 u or greater:
Sum 13 to 18 u
Sum 19 to 28 u
Total Cells 13 u or Greater/ml (in 10E4 units)

Number of
Cells
% of Cells (Count X 2
Step - Next 13u or
X Dilution
Step
greater
Factor
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Appendix C
Raw Data for the Sonication of the CB-Treated U937 Leukemia
Cells taken from 19 µ Steel Mesh Separation (1.25 µM CB, 36 hours, 20%
FBS Medium)

Tube

0 secs

2 secs

4 secs

6 secs

8 secs

10 secs

Days after
Sonication

# of Viable Big
Cells

# of Viable
Small Cells

0

9

3

12

75

2
4
6
9
11
0
2
4
6
9
11
0
2
4
6
9
11
0
2
4
6
9
11
0
2
4
6
9
11
0
2
4
6
9
11

18
17
7
2
0
4
23
10
17
2
0
3
12
4
6
9
----2
4
11
4
5
0
5
3
2
5
6
0
10
5
14
12
1
-----
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70
125
129
89
10
31
39
94
184
88
4
31
39
66
202
----5
10
24
50
188
63
1
15
20
52
181
95
3
27
38
128
183
-----

59
87
132
131
89
14
54
49
111
186
88
7
43
43
72
211
----7
14
35
54
193
63
6
18
22
57
187
95
13
32
52
140
184
-----

32
20
6
2
0
29
47
22
16
1
0
43
26
10
9
5
----29
31
31
6
3
0
75
17
7
9
3
0
77
15
27
9
1
-----

# of Total % Total Viable
Viable Cells
Big
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Appendix D
Distribution of cell sizes post-sonication

Appendix F
Power Output for the Sonicator Bath

Appendix E
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Power Output for Sonicator Bath

Power Output for Sonicator Bath
1
0.95

n=5
2 ml Distilled Water in
8 ml in 10 mm Diameter Tube.
250 ml Distilled Water in Bath

Watts (± Std Error)

0.9
0.85
0.8
0.75
0.7
0.65

Mean for n = 25; 0.768
Range: 0.42 to 1.05
Std Dev: 0.166
Std Error: 0.033

0.6
0.55
0.5
0

2

4

6

8

Seconds of Sonication

P=

ρ V CV ∆T
t

P= Output power
ρ=density of water = 1 g/ml
V=volume in test tube = 2 ml
Cv = specific heat of the water at constant volume = 4.186 J/(g°C)
T=temperature difference
t = time sonicated
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